Company Announcements

Director/PDMR Shareholding

Source: RNS
RNS Number : 5014F
Yourgene Health PLC
21 March 2022
 

 

Yourgene Health plc

("Yourgene" or the "Company")

 

Director Dealing

 

Manchester, UK - 21 March 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified 21 March 2022 that Hayden Jeffreys, Chief Operating Officer of the Company, purchased 355,450 ordinary shares today at 8.44p per share in his SIPP account.

 

Following the above transaction, Hayden Jeffreys is interested in 688,944 ordinary shares in the Company, representing approximately 0.09 per cent. of the Company's issued share capital.

 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
The Directors of the Company take responsibility for this announcement.

 

Yourgene Health plc

Lyn Rees, Chief Executive Officer

Tel: +44 (0)161 669 8122

investors@yourgene-health.com 

Barry Hextall, Chief Financial Officer


Joanne Cross, Director of Marketing




Cairn Financial Advisers LLP (NOMAD)

Tel: +44 (0)20 7213 0880

Liam Murray / James Caithie / Ludovico Lazzaretti




Singer Capital Markets (Joint Corporate Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / Tom Salvesen / George Tzimas




Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Tel: +44 (0)20 7710 7600

Nicholas Moore / Matthew Blawat / Ben Maddison




Walbrook PR Ltd (Media and Investor Relations)

Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: 07980 541 893 / Mob: 07584 391 303  

 

 

About Yourgene Health

 

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 

 

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Hayden Jeffreys

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Operating Officer

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Yourgene Health plc

b)

 

LEI

 

 

213800UUIT8BZE7QEH33

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 0.1p each



Identification code

ISIN: GB00BN31ZD89



b)

 

Nature of the transaction

 

 

Purchase of ordinary shares

 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




8.44p

355,450







d)

 

Aggregated information

N/A



- Aggregated volume




- Price




e)

 

Date of the transaction

 

 

21 March 2022

f)

 

Place of the transaction

 

UK

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHQFLFLLXLLBBF